Targeted Chemo‐Phototherapy in Red Light with Novel Doxorubicin and Iron(III) Complex‐Functionalized Gold Nanoconjugate (Dox‐Fe@FA‐AuNPs)
Chemistry – An Asian Journal · 2024
DOI: 10.1002/asia.202400616 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry – An Asian Journal, 2024. Verfasst von Maynak Pal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, National Institute of Technology Manipur, Langol, 795004, Imphal West, Manipur. Hauptthemen laut MEDLINE: Gold, Doxorubicin, Metal Nanoparticles, Nanoconjugates. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 82 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India, Board of Research in Nuclear Sciences (BRNS), Mumbai, Indian Council of Medical Research (ICMR).
Abstract (Originalsprache)
The anticancer efficacy of doxorubicin, an anthracycline‐based and FDA‐approved chemotherapeutic drug, is significantly hindered by acquired chemoresistance and severe side effects despite its potent anticancer properties. To overcome these challenges, we developed an innovative therapeutic formulation that integrates targeted chemotherapy and phototherapy within a single platform using gold nanoparticles (AuNPs). This novel nanoconjugate, designated as Dox‐Fe@FA‐AuNPs , is co‐functionalized with folic acid, doxorubicin, and an iron(III)‐phenolate/carboxylate complex, enabling cancer‐specific drug activation. Here, we report the synthesis, characterization, and comprehensive physico‐chemical and biological evaluations of Dox‐Fe@FA‐AuNPs . The nanoconjugate exhibited excellent solubility, stability, and enhanced cellular uptake in folate receptor‐positive cancer cells. The nanoconjugate was potently cytotoxic against HeLa and MDA‐MB‐231 cancer cells (HeLa: 105.5±16.52 μg mL −1 ; MDA‐MB‐231: 112.0±12.31 μg mL −1 ; MDA‐MB‐231 (3D): 156.31±19.35 μg mL −1 ) while less cytotoxic to the folate(−) cancer cells (MCF‐7, A549 and HepG2). The cytotoxicity was attributed to the pH‐dependent release of doxorubicin, which preferentially occurs in the acidic tumor microenvironment. Additionally, under red light irradiation, the nanoconjugate generated ROS, inducing caspase‐3/7‐dependent apoptosis with a photo‐index (PI) >50, and inhibited cancer cell migration. Our findings underscore the potential of Dox‐Fe@FA‐AuNPs as a highly effective and sustainable platform for targeted chemo‐phototherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, National Institute of Technology Manipur, Langol, 795004, Imphal West, Manipur.
- Department of Inorganic and Physical Chemistry, Indian Institute of Science Bangalore, Bangalore, 560012, Karnataka.
- Department of Biochemistry, AIIMS Bhopal, Saket Nagar, Bhopal, Madhya Pradesh.
- Department of Chemistry, National Institute of Technology Agartala, Jirania, 799046, Tripura West.
ORCID-Profile: Mithun Roy
Förderung
- Department of Biotechnology, Ministry of Science and Technology, India, Board of Research in Nuclear Sciences (BRNS), Mumbai
- Indian Council of Medical Research (ICMR)
Zitieren
APA
Pal, M., Bera, A., Masarkar, N., Upadhyay, A., Mukherjee, S., & Roy, M. (2024). Targeted Chemo‐Phototherapy in Red Light with Novel Doxorubicin and Iron(III) Complex‐Functionalized Gold Nanoconjugate (Dox‐Fe@FA‐AuNPs). Chemistry – An Asian Journal. https://doi.org/10.1002/asia.202400616
Vancouver
Pal M, Bera A, Masarkar N, Upadhyay A, Mukherjee S, Roy M. Targeted Chemo‐Phototherapy in Red Light with Novel Doxorubicin and Iron(III) Complex‐Functionalized Gold Nanoconjugate (Dox‐Fe@FA‐AuNPs). Chemistry – An Asian Journal. 2024. doi:10.1002/asia.202400616
BibTeX
@article{Pal2024,
author = {Pal, Maynak and Bera, Arpan and Masarkar, Neha and Upadhyay, Aarti and Mukherjee, Sukhes and Roy, Mithun},
title = {Targeted Chemo‐Phototherapy in Red Light with Novel Doxorubicin and Iron(III) Complex‐Functionalized Gold Nanoconjugate (Dox‐Fe@FA‐AuNPs)},
journal = {Chemistry – An Asian Journal},
year = {2024},
doi = {10.1002/asia.202400616}
}
EUVIMED